Greenrose Acquisition Corp. Stockholders Approve Business Combination
- All Stockholder Proposals Were Approved -
Continued here:
Greenrose Acquisition Corp. Stockholders Approve Business Combination
Category Archives: Global News Feed
HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thrombocytopenia in China
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase III trial in China of HMPL-523, a novel, investigational spleen tyrosine kinase (“Syk”) inhibitor, in adult patients with primary immune thrombocytopenia (“ITP”), an autoimmune disorder that can lead to increased risk of bleeding. The first patient received their first dose on October 27, 2021.
Supernus to Announce Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021
ROCKVILLE, Md., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the third quarter of 2021 after the market closes on Wednesday, November 3, 2021.
CytoDyn Announces FDA Accepts Revised Rolling Review Timeline for Resubmission of its BLA
Management expects the non-clinical and CMC sections of the BLA to be resubmitted to FDA in November
See original here:
CytoDyn Announces FDA Accepts Revised Rolling Review Timeline for Resubmission of its BLA
Phathom Pharmaceuticals Withdraws Public Offering
FLORHAM PARK, N.J., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the withdrawal of the previously announced, proposed primary and secondary public offering. With our strong balance sheet, we believe that current market conditions are not conducive to an offering on terms that would be in the best interests of our stockholders. We are well capitalized, with cash and cash equivalents of $225 million as of September 30, 2021, which we believe, together with the drawdown of the remaining $100 million under our term loan facility, will be sufficient to fund our operations into mid-2023.
Excerpt from:
Phathom Pharmaceuticals Withdraws Public Offering
argenx Reports Third Quarter 2021 Financial Results and Provides Business Update
– U.S. and Japan commercial teams fully staffed ahead of potential launches of efgartigimod in generalized myasthenia gravis (gMG) –
Read the rest here:
argenx Reports Third Quarter 2021 Financial Results and Provides Business Update
MDxHealth Announces Launch of Proposed Initial Public Offering of ADSs in the United States
NEWS RELEASE - REGULATED INFORMATIONINSIDE INFORMATION28 OCTOBER 2021, 07:00 CEST
Continued here:
MDxHealth Announces Launch of Proposed Initial Public Offering of ADSs in the United States
Novadip Biosciences announces EUR 19 million Series B financing backed by international investors
Novadip Biosciences announces EUR 19 million Series B financing backed by international investors
Read this article:
Novadip Biosciences announces EUR 19 million Series B financing backed by international investors
Vistin Pharma ASA: Third quarter 2021 financial results
Oslo, Norway, 28th of October 2021
Read the rest here:
Vistin Pharma ASA: Third quarter 2021 financial results